Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAIR: Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression in HIV-1
NCT02938520Phase 3Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- Oct 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Percentage of Participants With Virologic Failure (HIV-1 RNA >=50 Copies/mL) at 48 weeks. Started Oct 2016; status: active, not recruiting.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02938520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938520.